Follow us on Twitter
twitter icon@FreshPatents


Fatty Liver patents

      

This page is updated frequently with new Fatty Liver-related patent applications.




 Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders patent thumbnailCo-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
The present invention is directed to the use of co-therapy comprising administration of canagliflozin and phentermine for the treatment of obesity and obesity related disorders. More particularly, the present invention is directed to co-therapy for treating obesity, for promoting weight loss and/or for suppressing appetite; for treating, delaying, slowing the progression of and/or preventing metabolic disorders (including for example type 2 diabetes mellitus); for treating, delaying, slowing the progression of and/or preventing renal or fatty liver disorders (including for example nash, nafld, etc.); for treating, delaying, slowing the progression of and/or preventing sleep disorders (including for example sleep apnea); for providing cardiovascular protection; for treating, delaying, slowing the progression of and/or preventing cardiovascular events (including major adverse cardiac events (mace) such as myocardial infarction, unstable angina, cardiovascular death, revascularization, fatal or non-fatal cerebrovascular accident, peripheral arteriopathy, aortic events, hospitalization due to congestive heart failure, etc.); and/or for extending or prolonging life span..
Janssen Pharmaceutica Nv


 Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling patent thumbnailMethods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
The invention relates to the identification of new therapeutic methods for the fgf21 polypeptide or protein, or mutants, variants, and fusions thereof, for instance, in treating metabolic diseases associated defects in insulin signaling (e.g. Insulin receptor mutation disorders (insr disorders) and/or autoimmune insulin receptor disorders (type b insulin resistance)), defects in insulin production such as type 1 diabetes mellitus, mixed dyslipidemia, nonalcoholic fatty liver disease (nafld), and other metabolic disorders, and various lipodystrophies such as hiv-haart induced partial-lipodystrophy, and in reducing the mortality and morbidity of critically ill patients..
Novartis Ag


 Crystallized xylose isomerase in prevention of the development of non-alcoholic fatty liver disease patent thumbnailCrystallized xylose isomerase in prevention of the development of non-alcoholic fatty liver disease
The present invention relates to the composition comprising crystalline xylose-isomerase and at least one salt of a metal and/or alkaline earth metal for the treatment and prevention of non-alcoholic fatty liver disease and other fructose-related disorders.. .
Sciotec Diagnostic Technologies Gmbh


 Methods for treating metabolic disorders using fgf patent thumbnailMethods for treating metabolic disorders using fgf
The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.. .
Salk Institute For Biological Studies


 Mitochondrial-derived peptide mots3 regulates metabolism and cell survival patent thumbnailMitochondrial-derived peptide mots3 regulates metabolism and cell survival
Mots3 is a novel polypeptide. Methods of treating diseases such as diabetes, obesity, fatty liver, and cancer using mots3 and pharmaceutical compositions thereof are disclosed herein..
The Regents Of The University Of California


 Pharmaceutical composition containing gpr119 ligand as active ingredient for preventing or treating non-alcoholic fatty liver disease patent thumbnailPharmaceutical composition containing gpr119 ligand as active ingredient for preventing or treating non-alcoholic fatty liver disease
The present invention relates to a pharmaceutical composition containing a g protein coupled receptor 119 (gpr119) ligand as an active ingredient for preventing or treating non-alcoholic fatty liver disease. More particularly, it was confirmed that the gpr119 ligand, which has been developed as only an anti-diabetic drug, exhibits superior effects on the treatment of non-alcoholic fatty liver and the signal pathways in hepatocytes therefor differ from the signal pathways in the small intestine and the pancreas exhibiting anti-diabetic effects, whereby the gpr119 ligand can be useful to treat non-alcoholic fatty liver..
Snu R&db Foundation


 Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome patent thumbnailCompositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome
The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis, atherosclerosis, obesity, hyperglycemia, metabolic syndrome, and related aspects of and conditions associated with metabolic syndrome. The compositions and methods disclosed herein are useful for regulating the lipid balance (lipid homeostasis) in a subject.
Vanderbilt University


 Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof patent thumbnailBerberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof
The invention provides various novel compositions of berberine in combination with pharmacologically active organic acids, and related methods of their use in treating various diseases or disorders. The invention further provides various novel compounds prepared from berberine and pharmacologically active organic acids and prepared from ursodeoxycholic acid and pharmacologically active organic bases, and pharmaceutical compositions thereof, and methods of their preparation and therapeutic use in treating and/or preventing various diseases or disorders.
Shenzhen Hightide Biopharmaceutical, Ltd.


 Composition for preventing or treating fatty liver diseases patent thumbnailComposition for preventing or treating fatty liver diseases
The present invention relates to a pharmaceutical composition for preventing or treating fatty liver diseases, containing (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1h-indol-7-yl]amine or a pharmaceutically acceptable salt thereof as active ingredients. (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1h-indol-7-yl]amine or a pharmaceutically acceptable salt thereof, according to the present invention, can effectively inhibit fatty liver, hepatitis and hepatic fibrosis and can be useful for preventing or treating nafld, and in particular, nash..
Lg Life Sciences Ltd.


 Method to prepare ganoderma lucidum polysaccharides possessing protective activities on fatty liver disease patent thumbnailMethod to prepare ganoderma lucidum polysaccharides possessing protective activities on fatty liver disease
The present invention provides a method to prepare polysaccharides from ganoderma lucidum. The prepared polysaccharides can reduce liver weight and liver lipid content in humans and animals.
Chang Gung Biotechnology Corp.


Free raptor reduces aging- and obesity-induced fatty liver

The present invention also provides a method of reducing a subject's hepatic and plasma triglyceride levels comprising administering to a subject in need thereof a pharmaceutical composition comprising a pharmaceutical carrier and a compound that inhibits glucagon signaling in liver cells in an amount effective to reduce the subject's hepatic and plasma triglyceride. .

Oral formulations mimetic of roux-en-y gastric bypass actions on the ileal brake; compositions, methods of treatment, diagnostics and systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and type 2 diabetes.

In other aspects, the invention provides ileal brake hormone releasing compositions, methods of treatment, diagnostics, and related systems useful in selective control of appetite, stabilizing blood glucose and insulin levels, and treating gastrointestinal disorders in a similar manner to rygb surgery, but having at least 20% of the potency to stimulate the hormonal response of the ileal brake of humans.. .

Oral formulations mimetic of roux-en-y gastric bypass actions on the ileal brake; compositions, methods of treatment, diagnostics and systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and t2d

In other aspects, the invention provides ileal brake hormone releasing compositions, methods of treatment, diagnostics, and related systems useful in selective control of appetite, stabilizing blood glucose and insulin levels, and treating gastrointestinal disorders in a similar manner to rygb surgery, but having at least 20% of the potency to stimulate the hormonal response of the ileal brake of humans.. .

Systems, devices and methods for performing medical procedures in the intestine

A method for performing a medical procedure in an intestine of a patient is provided. The method comprises providing a system comprising: a catheter for insertion into the intestine, the catheter comprising: an elongate shaft comprising a distal portion; and a functional assembly positioned on the shaft distal portion and comprising at least one treatment element.
Fractyl Laboratories, Inc.

Method for assessment of hepatic function and portal blood flow

A method for estimating portal blood flow and hepatic function in a subject is provided. In one example, the stat test is an in vitro simplified, convenient test intended for screening purposes that can reasonably estimate the portal blood flow from a single blood sample taken 60 minutes after orally administered deuterated-cholate.
The Regents Of The University Of Colorado, A Body Corporate

Use of a statin compound as topical drug for treating obesity, diabetes, hypertension and hyperlipemia

The invention discloses a use of a statin compound in the preparation of local drugs for improving lipid metabolism and treating obesity, hypertension, hyperlipidemia, fatty liver and hyperglycemia; and statin compound local compositions for improving lipid metabolism and treating obesity, hypertension, fatty liver, hyperlipidemia, atherosclerosis, coronary heart disease, apoplexy and other cardiovascular and cerebrovascular diseases, and drug formulation and preparation method thereof.. .
Peking University Third Hospital

Modulation of nlgn4 expression, nk cell activity in non-alcoholic fatty liver disease (nafld)

The present invention provides a method of diagnosing and/or monitoring a liver disorder in a subject. The method calls for isolating an immune cell population from a biological sample of the subject; and detecting expression level of an nlgn4 gene product in the immune cell population using nlgn4 specific primers or nlgn4 specific probes..
Hadasit Medical Research Services And Development Ltd.

Glucagon and glp-1 co-agonist compounds

The present invention provides glucagon and glp-1 co-agonist compounds that are useful in the treatment of type 2 diabetes, obesity, nonalcoholic fatty liver disease (nafld) and/or nonalcoholic steatohepatitis (nash).. .
Eli Lilly And Company

Lysosomal acid lipase therapy for nafld and related diseases

The present invention comprises methods and compositions for the treatment or alleviation of nafld (non-alcoholic fatty liver disease) and those conditions associated with nafld, including fatty liver disease, nonalcoholic steatohepatitis (nash) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for treating the metabolic syndrome.
Children's Hospital Medical Center

Method to prepare hirsutella sinensis polysaccharides possessing protective activities on fatty liver disease

The present invention provides a method to prepare polysaccharides from hirsutella sinensis. The prepared polysaccharides can reduce liver size, weight and the number and size of liver lipid vacuoles, as well as serum triglycerides and serum aspartate aminotransferase levels in humans and animals.
Chang Gung Biotechnology Corp.

Novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty livers diseases and atherosclerosis

5-cholesten, 3β, 25-diol, disulfate (25hcds) has been found to be an authentic pparγ agonist and lxr antagonist, and is used for the therapy of lipid disorders and inflammatory diseases, including without limitation fatty liver, inflammatory bowel, and atherosclerotic diseases.. .
Virginia Commonwealth University

Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease

The present invention relates to the field of gene therapy and, more particularly, to methods for the prevention and/or treatment of non-alcoholic fatty liver disease (nafld). The viral vectors disclosed in the present invention are preferably parvoviral vector, more preferably adeno-associated vectors (aav) containing the gene encoding sirtuin 1 (sirt1) in the prevention and/or treatment of nafld.
Universitat Autònome De Barcelona

Methods for treating metabolic disorders using fgf

The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.. .
Salk Institute For Biological Studies

Ketohexokinase (khk) irna compositions and methods of use thereof

The present invention relates to rnai agents, e.g., double-stranded rnai agents, targeting the ketohexokinase (khk) gene, and methods of using such rnai agents to inhibit expression of khk and methods of treating subjects having a khk-associated disorder, e.g., liver disease (e.g., fatty liver, steatohepatitis), dyslipidemia (e.g., hyperlipidemia, high ldl cholesterol, low hdl cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia), disorders of glycemic control (e.g., insulin resistance, diabetes), cardiovascular disease (e.g., hypertension, endothelial cell dysfunction), kidney disease (e.g., acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules), metabolic syndrome, adipocyte dysfunction, visceral adipose deposition, obesity, hyperuricemia, gout, eating disorders, and excessive sugar craving.. .
Alnylam Pharmaceuticals, Inc.

Methods for the treatment and prevention of renal disorders and fatty liver disorders

The present invention is directed to methods for treating, delaying, slowing the progression of and/or preventing disorders comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising, consisting or consisting essentially of (a) canagliflozin and (b) one or more ace inhibitors or one or more arbs or one or more ppar-gamma agonists; and to methods for treating, delaying, slowing the progression of and/or preventing fatty liver disorders (for example, nash or nafld), comprising administering to a subject in need thereof a therapeutically effective amount of canagliflozin.. .
Janssen Pharmaceutica Nv

Use of caspase-2 inhibitors to treat and prevent the metabolic syndrome

Methods and compositions for treatment of obesity, insulin resistance, hyperinsulinemia, type 2 diabetes mellitus, dyslipidemia, and nonalcoholic fatty liver disease are discloses. The methods and compositions relate to inhibition of caspase-2..
Duke University

Pomegranate skin extract for treating fatty liver

Use of a pomegranate skin extract for use in the treatment of metabolic syndrome, more particularly, fatty liver disease. More particularly, the pomegranate skin extract is used in inhibiting body weight gain in the prevention and/or the treatment of fatty liver disease in mammals..
Nestec S.a.

Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders

This invention is in the area of improved anti-ap2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone ap2/fabp4 (referred to as “ap2”) for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for ap2 mediated disorders are disclosed in which serum ap2 is targeted and the biological activity of ap2 is neutralized or modulated using low-binding affinity ap2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease..
Ucb Biopharma Sprl

Methods for treating fatty liver disease

In certain aspects, the present invention provides compositions and methods for treating fatty liver disease by administering an antagonist of an actriib signaling pathway. Examples of such antagonists include actriib polypeptides, anti-actriib antibodies, anti-myostatin antibodies, anti-gdf3 antibodies and anti-activin a or b antibodies.
Acceleron Pharma Inc.

Biguanide derivative, a preparation method thereof, and a pharmaceutical composition containing the biguanide derivative as an active ingredient

A biguanide derivative compound with n1-n5 substitution, which is represented by formula 1, or a pharmaceutically acceptable salt thereof a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of ampkα and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc..
Immunomet Therapeutics Inc.

Chemical ablation and treatment for various diseases

Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, nonalcoholic fatty liver disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients.
Neurotronic, Inc.

Differential diagnosis of liver disease

The present invention relates to the substantially non-invasive diagnosis of liver disease, especially to enable intervention in the progression of such disease at an early stage. This invention further relates to the use of plasma biomarkers to differentiate nonalcoholic steatohepatitis (nash) from nonalcoholic fatty liver (nafl) and non-nonalcoholic fatty liver disease (nafld), and normal controls.
The Regents Of The University Of California

Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states

Described herein are compositions including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided are methods of administering to a subject a composition including at least one omega-3 fatty acid (either in the triglyceride, ester or free fatty acid ester form) and at least one surface active agent, wherein the compositions form micelles when in contact with an aqueous medium, and the bioavailability of the omega-3 fatty acid is substantially independent of a food effect.
Sancilio & Company, Inc.



Fatty Liver topics:
  • Fatty Liver
  • Liver Disease
  • Alcoholic Fatty Liver
  • Steatohepatitis
  • Nonalcoholic Steatohepatitis
  • Metabolic Syndrome
  • C Syndrome
  • Hyperlipidemia
  • Insulin Resistance
  • Hepatitis A
  • Dyslipidemia
  • Atherosclerosis
  • Arteriosclerosis
  • Cardiovascular
  • Vascular Diseases


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Fatty Liver for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Fatty Liver with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.0824

    file did exist - 2691

    2 - 1 - 52